Chimin(SH:603222)2025-01-24 09:40Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -15 million and -10 million yuan, a reduction in losses compared to -65.48 million yuan in the same period last year[4]. - The company anticipates a net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, to also be between -15 million and -10 million yuan for 2024[4]. - The expected earnings per share for 2024 is -0.12 yuan[8]. - The company aims to reduce losses in 2024 compared to the previous year's performance[7]. Research and Development - Research and development expenses for 2024 are estimated to be approximately 41.52 million yuan, an increase of 43.67% compared to the same period last year[9]. - The company completed the research and development of new skincare products, including facial masks, essence, and eye cream, which were launched in the fourth quarter of 2024[9]. Operational Impact - The direct property loss from the typhoon disaster affecting the company's subsidiary is estimated at about 30 million yuan, impacting the hospital's operational performance in 2024[9]. - The company did not incur significant impairment provisions in 2024, unlike the previous year where it recorded a total of 79.38 million yuan in impairment provisions[9]. Financial Reporting - The financial data provided is preliminary and has not been audited by registered accountants, with the final figures to be disclosed in the audited annual report[10][11]. - The company emphasizes that there are no significant uncertainties affecting the accuracy of this earnings forecast[10].